10 Best Japanese Stocks To Watch Right Now

10 Best Japanese Stocks To Watch Right Now: Keryx Biopharmaceuticals Inc.(KERX)

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company?s products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types. The company is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease o n dialysis. Keryx Biopharmaceuticals, Inc. has commercial license agreements with Zentaris AG for the development of KRX-0401; Panion & BF Biotech, Inc. for the development and marketing of Zerenex; and Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. The company was founded in 1997 and is based in New York, New York.

Advisors' Opinion:

• [By MONEYMORNING.COM]

  On August 29, 2012, shares of Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a company focused on pharmaceutical products for patients with renal disease, closed for the day's session at $2.06. Exactly two years later, on August 29, 2014, the same stock closed at $18.19.

• [By Keith Speights]

  For example, Keryx Biopharmaceuticals (NASDAQ: KERX  ) reported no revenue for 2012. Not a dime. The company lost $22.7 million last year and even more the year! before that. However, those financial results really aren't important at this point.

• [By Bryan Murphy]

  Just so there's no misunderstanding, Keryx Biopharmaceuticals (NASDAQ:KERX) hasn't run into any unexpected trouble with one of its drugs. There's no FDA impasse on the horizon that should be pushing KERX lower. This isn't even a judgment call on the company or its potential with flagship kidney disease drug Auryxia. This is just a reality check for the stock, which as is often the case with biotech stocks, has taken on a predictable life of its own. Problem: The predictive clues just turned dire.

• [By gurujx]

  Keryx Biopharmaceuticals Inc. (KERX): CFO James F. Oliviero III Sold 109,500 Shares

  CFOJames F. Oliviero IIIsold 109,500 shares of KERX stock on 12/30/2013 at the average price of $12.64. James F. Oliviero III owns at least 476,429 shares after this. The price of the stock has decreased by 3.32% since.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/10-best-japanese-stocks-to-watch-right-now-2.html